Based on our current data and previous findings [20, 27, 29] from our group we hypothesised that using Thio-S or Thio-2 inhibitors of BAG-1 protein-protein interactions in combination with trastuzumab, a first-line treatment for HER2+ breast cancer [4], would further restrict growth of HER2+ breast cancer cells. The gene discussed is ERBB2; the disease is breast cancer.